Purin-Ago: Non-nucleotide agonists of the P2Y11-receptor with immunosuppressant effect
Purinergic receptors have been in the focus of drug discovery for many years. This invention provides nonnucleotide
agonists of the P2Y11-receptor. The agonists ensure high specificity among P2-receptors which is a key to tolerability of compounds meant for applications in longterm treatment settings. Activation of the P2Y11-receptor leads to a variety of effects in the modulation of immune system activity. For example release of immune modulatory thrombospondin-1 is induced, while lipopolysaccharide (LPS)-stimulated release of the pro-inflammatory cytokine interleukin-12 (IL- 12) is inhibited by activation of the P2Y11-receptor.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…